Emergent garners $29 million for new anthrax vaccine

first_img Sep 9 CIDRAP News story “HHS funds work on new anthrax antitoxin” Sep 26, 2008 (CIDRAP News) – Emergent BioSolutions announced today that it has received a $29.7 million contract from the federal government to continue work on another of its next-generation anthrax vaccine candidates. A next-generation anthrax vaccine would help the US military more easily inoculate troops. Soldiers in high-risk areas such as the Middle East typically receive six doses of BioThrax over 18 months, followed by annual boosters. The military has said a next-generation anthrax vaccine should ideally require fewer doses and have fewer side effects. Daniel J. Abdun-Nabi, Emergent’s president and chief operating officer, said in the statement that the grant is encouraged by federal support for its AV7909 anthrax vaccine candidate. “We look forward to continuing to work with the US government to advance all aspects of AV7909, as it pursues a multi-prong approach in responding to the ongoing threat of bioterrorism,” he said. On Sep 3, Emergent announced that it had won a $24.3 million federal contract for an anthrax monoclonal antibody treatment called AVP-21D9. In its statement today the company said it was also developing a polyclonal anthrax immunoglobulin candidate for intravenous treatment for patients who have anthrax infections. Emergent’s AV7909 anthrax vaccine consists of BioThrax (also known as Anthrax Vaccine Adsorbed), plus an adjuvant called CPG 7909, licensed from Pfizer, Inc. A clinical trial of CPG 7909 added to BioThrax showed that anti-protective antigen (PA) titers increased sixfold and reduced the time to peak response from 6 weeks to 3 weeks compared with BioThrax alone, Emergent said in its statement. Also, the two doses of AV7909 elicited the same anti-PA antibody levels as three doses of BioThrax.center_img See also: Sep 26 Emergent BioSolutions press release Of the 3-year contract, $24.9 million will cover the manufacturing of clinical lots, nonclinical safety and efficacy studies, and stability studies to determine if the vaccine can be stored without refrigeration, which is a key requirement for the new vaccine, Emergent said. The remaining $4.8 million would fund a phase 1 clinical trial if the company and the government exercise that option. Emergent, based in Rockville, Md., announced the contract from the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) in a press release today. The company makes BioThrax, the nation’s only licensed anthrax vaccine, and is also developing a recombinant anthrax vaccine and an anthrax monoclonal antibody to block the anthrax toxin.last_img read more

Sports Minister seeks partnership with MultiChoice

first_imgRelatedPosts Minister gives condition for resumption of contact sports Minister pledges support for development of AI, robotics in Nigeria MultiChoice unveils sport channels, content line-up Minister of Youth and Sports Development, Sunday Dare, has declared his ministry’s readiness to partner with MultiChoice Nigeria in its bid to revamp the country’s sports sector. The minister made the declaration in Abuja on Thursday when John Ugbe, Chief Executive Officer, MultiChoice Nigeria paid him a courtesy visit in his office. Dare stated that the ministry has, as its major agenda, a reset of the sports sector to ensure a vibrancy, a goal he believes MultiChoice is well positioned to help bring to fruition. Components of the envisaged reset, the minister said, include a revamp of infrastructure, deliberate talent development initiatives and drive for corporate sector involvement to accelerate financial growth of the sector. Responding, Ugbe thanked the minister for seeing MultiChoice as a partner in the bid to develop sports in the country. Ugbe noted that MultiChoice’s commitment to sports development, which began decades ago, will remain unwavering. He noted that the company is the biggest investor in Nigerian sports as well as preeminent supporter of Nigerian boxing through GOtv Boxing Night, GOtv Boxing Night NextGen Search and the recently introduced GOtv Boxing Night Mini, each of which has rescued the sport from the wretched state into which it fell for over two decades. The MultiChoice boss also used the opportunity to invite the minister to grace GOtv Boxing Night 20, which holds on 28 December at the Tafawa Balewa Square, Lagos, and will feature a World Boxing Federation Intercontinental heavyweight title bout among others. Ugbe listed the company’s other footprints in sports as including the company sponsored the Nigerian Basketball League for years, during which the Nigerian team qualified for the Olympic Games; years of officially broadcasting the Nigerian Professional Football League and continuous live-broadcast matches of the Super Eagles, Flying Eagles and Golden Eaglets in addition to matches of the prestigious European football leagues as well as other major global sporting events. To build the capacity of the country’s sports administrators, Ugbe added, the company funded a training programme in conjunction with the University of Nigeria Nsukka and South Africa’s Wits University to raise sports administration standards. Responding, the minister expressed hope that the desired partnership has the potential to bring about the much-needed renaissance in the sector. He mandated staff of the ministry, led by Maria Wophill, a Deputy Director, to work with MultiChoice to bring the partnership to life. Ugbe was accompanied on the visit by Felix Awogu, Executive Head, OB and Studio, SuperSport; Caroline Oghuma, Executive Head, Corporate Affairs, MultiChoice Nigeria; and Gozie Onumonu, Head, Regulatory Affairs, MultiChoice.Tags: John UgbeMultiChoice NigeriaSunday Darelast_img read more